This content is only available within our institutional offering.
13 Feb 2026
Singer Capital Markets - SkinBio Therapeutics - Experienced Board take control
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
Singer Capital Markets - SkinBio Therapeutics - Experienced Board take control
SkinBioTherapeutics Plc (SBTX:LON) | 12.4 -0.9 (-36.5%) | Mkt Cap: 32.0m
- Published:
13 Feb 2026 -
Author:
Karl Keegan -
Pages:
3 -
Stuart Ashman has resigned as CEO of SBTX, following being suspended by the Board. This action was taken after an investigation into matters relating to his conduct. The Board has instigated a full investigation into this matter, supported by its professional advisors. We make no changes to our forecasts or recommendation and await the conclusion of the in-depth investigation.